Cannabis Europa, the leading B2B conference for the European cannabis industry, has announced the full programme for its 2026 London edition, with a number of patient issues featuring across two days of sessions and talks at The Barbican on 26 and 27 May. More than 70 speakers, including regulators, investors, clinicians and operators, will address over 1,000 delegates.
The London 2026 edition arrives at a moment of considerable consequence for the sector. Europe’s legal medical cannabis market is projected to surpass €1.5 billion according to Prohibition Partners, regulatory frameworks are maturing, institutional capital is increasing, and consolidation is reshaping the competitive landscape.
Day one opens with a State of Play session, addressing issues with the current prescribing framework and asking whether the country can move from caution to action after nearly eight years of limited NHS access to medical cannabis.
Later on, a panel will address two of the most common problems faced by people prescribed cannabis in the UK. Titled Policy in Practice: From Workplace Testing to Driving – How Does UK Law Impact Patients, the session will look at the lack of guidelines issued to public bodies and what “policy in practice” should look like when the law recognises a medical defence, but systems and institutions still struggle to apply it consistently, from roadside stops to HR decisions.
In the afternoon, leafie editor Liam O’Dowd hosts a panel discussing the latest research into tolerance breaks and the implications for medical cannabis use. Day two features a dedicated session on cannabis and the gender health gap, addressing endometriosis, menopause and conditions long underserved by conventional medicine. The second day wraps up with a patient’s roundtable in The Greenhouse, while over on the main stage, a closing panel will ask whether Europe’s medical cannabis market might shift from flower to pharmaceutical-grade formats.
“Cannabis Europa exists because the industry’s most consequential conversations require the right room,” said co-founder Stephen Murphy. “The London 2026 programme reflects where the European market genuinely stands – more sophisticated than ever before, consolidating, and demanding rigorous analysis.”
Alongside talks, networking and exhibitors, the 2026 Business of Cannabis Awards will be presented on the main stage on 26 May, recognising the companies, clinicians and advocates driving measurable progress across the industry.
Tickets are available online at cannabis-europa.com. Patients interested in attending the event are invited to apply for a concession ticket by emailing info@cannabiseuropa.com
